WuXi Biologics (Cayman) Inc. provided earnings guidance for the year ended December 31, 2018. Based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the year ended December 31, 2018, it is expected that the net profit of the Group for the year ended December 31, 2018 will be more than 245% of that for the year ended December 31, 2017. Such increase was primarily attributable to: leading technology platform, competitive timeline and strong execution track record contributing to more market share and new integrated projects being added to pipeline; strong growth in revenue, as a result of more projects entering into late-phase by the success of the Group's ‘Follow-the-Molecule’ strategy; milestone revenue with relatively high gross margin; considerable interest income as a result of improved cash flow; and foreign exchange gains recorded for the year ended December 31, 2018 as compared to significant foreign exchange losses for the year ended December 31, 2017.